Pharmaceuticals China

China Shingles Vaccines Market Analysis, 2024–2034

China Shingles Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Type, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

China · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $431.3 Mn Estimated value
Estimate 2025 $468.3 Mn 9.1% of the global market
Projected 2034 $984.1 Mn 110.1% Adds $515.7 Mn over 9 forecast years
CAGR 2025–2034 8.6% Faster than 39% of 180 Pharmaceuticals markets here
Key players 5
  • China is 9.09% of the global market.
  • In APAC, the largest is China (this report) at $468.3 Mn.
  • Fastest growing: India at 10.4% a year.
  • China ranks 1st of 10 by size in APAC.

Market size projection

China

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$515.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Shingles Vaccines Market market size by year, China
YearMarket sizeChange that yearSince 2025
2024 (estimate) $431.3 Mn — —
2025 (base) $468.3 Mn +$37.1 Mn —
2026 (forecast) $508.6 Mn +$40.3 Mn +8.6%
2027 (forecast) $552.4 Mn +$43.7 Mn +17.9%
2028 (forecast) $599.9 Mn +$47.5 Mn +28.1%
2029 (forecast) $651.4 Mn +$51.6 Mn +39.1%
2030 (forecast) $707.5 Mn +$56.0 Mn +51.1%
2031 (forecast) $768.3 Mn +$60.8 Mn +64.1%
2032 (forecast) $834.4 Mn +$66.1 Mn +78.2%
2033 (forecast) $906.1 Mn +$71.8 Mn +93.5%
2034 (forecast) $984.1 Mn +$77.9 Mn +110.1%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The China Shingles Vaccines Market Analysis Executive Summary

Shingles vaccines prevent herpes zoster, a painful rash caused when the chickenpox virus wakes up again, mostly in older adults.

Key segments of the shingles Vaccines market include type (Recombinant Vaccines and Live Attenuated Vaccines) and age (50-64 Years, 65 Years and Above and Immunocompromised Adults).

China Shingles Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the shingles Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the shingles Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the shingles Vaccines market.

Competitive Landscape for Shingles Vaccines Market in China

The shingles Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Shingles Vaccines Market in China

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for shingles Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in China.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Shingles Vaccines right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Shingles Vaccines in context

China compared

  • Health spending per person: 763 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 3.11 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 14.9% of people (2025). World: 10.4% of people (2025). 6th highest of the 16 countries we cover in APAC.[3]

Questions, answered with public data

How many clinical trials on Shingles Vaccines are running in China?
15 studies are recruiting, active or about to start in China.[4]
How much research is published on Shingles Vaccines?
PubMed lists 33 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in China. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in China

See all

Related on vaccines and geriatric

See the topic